SeaPRwire

CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity

SHENZHEN, CHINA, Mar 5, 2026 – (ACN Newswire) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that self-developed innovative drug INHBE-targeting small nucleic acid drug CMS-D008 injection (“CMS-D008”) received the Drug Clinical Trial Approval Notice issued by National Medical Products Administration (“NMPA”) on 4 March 2026. The NMPA has approved the conduct of clinical trials of CMS-D008 injection for overweight or obese individuals. About CMS-D008 CMS-D008 is a novel siRNA therapy administered by subcutaneous injection. CMS-D008 targets and reduces the hepatic expression of the inhibin subunit beta E (INHBE) gene and lowers the level of Activin E protein encoded by INHBE, which blocks Activin E-ALK7 signaling and reduces fat accumulation effectively. Preclinical studies suggested that CMS-D008 efficiently and sustainably suppressed INHBE expression. In the diet-induced obesity model, CMS-D008 enhanced weight loss by reducing fat mass while retaining lean mass with a good safety profile. It demonstrates potentially better prospects for high-quality, long-term weight loss that boosts fat-specific loss while preserving muscle mass. In the future, it may be developed for the treatment of overweight/obesity, abdominal obesity, and related metabolic diseases. Fat Loss, muscle preserved: a potentially better therapeutic option for overweight/obesity Overweight or obesity is a chronic, progressive, relapsing disease characterized by excessive accumulation or abnormal distribution or function of body fat[1]. World Obesity Atlas 2025 Report projected that the global proportion of overweight and obese adults will rise to 50%, with nearly 3 billion adults impacted by high body mass index (BMI), and the population of adults who are overweight or obese in China is projected to reach 515 million by 2030[2]. Existing GLP-1RAs have been proven to be effective for the treatment of overweight and obesity. The main actions of GLP-1RAs are to suppress appetite by acting on the central nervous system and to delay gastric emptying[3]. INHBE’s novel mechanism of action differs from GLP-1RAs. INHBE is identified through genome-wide association studies. Populations with loss of function in INHBE are associated with favorable fat distribution and beneficial metabolic characteristics[4]. Targeted inhibition of INHBE might be more conducive for long-term weight management at the genetic level with precisely lower visceral fat and favorable metabolic profiles. CMS-D008 teams up with CMS-D005: highly effective weight loss plus long-term maintenance, building a more comprehensive weight-loss solution CMS-D008 will synergize with CMS-D005, a self-developed innovative drug currently in clinical development. CMS-D008 reduces fat without sacrificing muscle mass by precisely inhibiting INHBE gene expression; while CMS-D005, as a GLP-1R/GCGR dual agonist, can effectively reduce liver fat while losing weight. The synergy between these two drugs will achieve highly effective weight loss benefits and long-term maintenance of results, jointly enhancing the Group’s R&D capabilities and product competitiveness in the field of obesity/metabolic treatment. Furthermore, leveraging the Group’s mature network resources in the field of cardiovascular and metabolic diseases, the drug’s R&D and commercialization process will be accelerated, providing patients with more comprehensive and innovative treatment options. The Group is actively preparing to initiate relevant clinical trials and strives to launch the Product as soon as possible. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardiovascular-kidney-metabolic/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference: 1. Chinese Society of Endocrinology. Guideline for chronic weight management and clinical practice of anti-obesity medications(2024 version). Chinese Journal of Endocrinology and Metabolism. 2024,40(7):545-564. 2. World Obesity Federation. World Obesity Atlas 2025. London: World Obesity Federation, 2025. https://data.worldobesity.org/publications/?cat=23 3. Zhikai Zheng, Yao Zong, Yiyang Ma, Yucheng Tian, Yidan Pang, Changqing Zhang, Junjie Gao. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Sig Transduct Target Ther 9, 234 (2024). doi: 10.1038/s41392-024-01931-z 4. Parsa Akbari, Olukayode A Sosina, Jonas Bovijn, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes. Nat Commun.2022 Aug 23;13(1):4844. doi: 10.1038/s41467-022-32398-7. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.

SeaPRwire

Core Concepts Physiotherapy Partners with Podiatry Quest to Deliver Enhanced Assessments for Patients with Plantar Fasciitis

Singapore – March 05, 2026 – (SeaPRwire) – Core Concepts Physio, one of Singapore’s leading physiotherapy providers, has announced an expanded collaborative programme with podiatry service provider, Podiatry Quest, to offer enhanced, multidisciplinary assessments for patients experiencing plantar fasciitis and stubborn heel pain. Plantar fasciitis remains one of the most common and persistent causes of heel pain among adults, especially those with active lifestyles or occupations involving long hours on their feet. Often treatment seeks to address only one aspect of the condition rather than the full movement chain, which leads to recurring pain as other aspects remain unresolved. To bridge this gap, the two clinics have formalised a joint assessment pathway that evaluates plantar fasciitis from both the top-down (physiotherapy) and the bottom-up (podiatry) so as to ensure that no contributing factor is overlooked. A Smarter, More Complete Way to Diagnose Heel Pain Physiotherapy and podiatry traditionally manage different elements of plantar fasciitis. Physiotherapists focus on mobility, strength, gait and load tolerance, while podiatrists address foot posture, footwear, ground forces and orthotic support. The new integrated pathway combines both perspectives into a single, coordinated evaluation which results in: More accurate, holistic diagnoses Fully optimised treatment strategies Fewer flare-ups and recurrences Clearer, consistent guidance for patients Faster and more sustainable outcomes “Many patients struggle because plantar fasciitis isn’t caused by just one issue,” said Mr Chng Chye Tuan, Senior Principal Physiotherapist at Core Concepts Physiotherapy. “It’s a movement chain problem involving the foot, calf, ankle mobility, daily load and footwear. When physiotherapists and podiatrists work together, we address every contributing factor — not just the symptoms.” A Case Study Demonstrating Collaborative Success In a recent case, a 42-year-old recreational runner sought help after six months of persistent heel pain. Physiotherapy improved his morning pain and running tolerance, but he continued to experience flare-ups following long work shifts. A podiatry assessment revealed prolonged pronation, footwear-related loading issues and inadequate shock absorption. With customised orthoses and tailored footwear recommendations, the patient’s daily load decreased significantly — allowing physiotherapy progress to continue without setbacks. Within 10 weeks of coordinated care, he achieved pain-free mornings, comfortable workdays and full return to running. “This case reflects what we see frequently,” said Mr Yeo Boon Kiak, Principal Podiatrist at Podiatry Quest. “Physiotherapy builds tissue capacity, strength and movement control. Podiatry reduces unnecessary strain and optimises how forces enter the foot. When combined, this creates the ideal environment for long-lasting recovery.” Making Multidisciplinary Care Accessible Nationwide Through this collaboration, patients with plantar fasciitis now benefit from: Joint physiotherapy–podiatry assessments Aligned clinical decision-making Consistent communication across providers A thorough evaluation of both the cause and consequence of heel pain A fully optimised recovery pathway “Our multidisciplinary team brings together the best of both professions,” said Mr Chng Chye Tuan. “Whether someone is a runner, a frequent traveller or stands long hours at work, this collaboration ensures their care is comprehensive, precise and built around their real-life demands.” About Core Concepts Physiotherapy Core Concepts Physio is one of Singapore’s largest private physiotherapy groups, offering evidence-based musculoskeletal and sports physiotherapy across multiple clinic locations. Their multidisciplinary approach allows clients to benefit from integrated care, ensuring complete and effective recovery. Know more please contact marketing@coreconcepts.com.sg or call +65 62263632 or visit our office at 6 Raffles Quay, #11-01, Singapore 048580. About Podiatry Quest Podiatry Quest specialises in diagnosing and treating foot, ankle and lower limb conditions. Led by experienced podiatrists, the clinic offers services such as customised orthoses, biomechanical assessments, gait analysis and comprehensive podiatric care. Contact Details Organization: Core Concepts Pte Ltd Contact: Clemence Lim Email: marketing@coreconcepts.com.sg Website: https://www.coreconceptsphysio.sg

SeaPRwire

Experts Discuss AI Technology Diffusion and Asia’s Development Prospects — “Technology Diffusion and Asia Prosperity” Seminar Held in Singapore

On February 27, the seminar themed “Technology Diffusion and Asia Prosperity” was held in Singapore. The event was hosted by Singapore-based consultancy Edge Research and marked the launch of its “Asia Prosperity Initiative.” Experts and representatives from policymaking, academia, and industry gathered to engage in in-depth discussions on trends in AI technology diffusion, the development of AI agents, and the future of regional AI governance. Technology Diffusion Drives Social Transformation; Youth Development Pathways Being Rewritten During the roundtable session on “How Responsible Technology Diffusion can enable a Prosperous Asia”, participants focused on the impact of AI development on employment structures, education systems, and talent cultivation models. Professor Lawrence LOH, Director of Centre for Governance and Sustainability at the National University of Singapore Business School, noted that the main arena of frontier technological innovation has gradually shifted from traditional universities to corporations. Technology companies such as Google in the United States, Alibaba and Tencent in China have become key engines of AI innovation. Drawing on his teaching observations, he pointed out that certain job positions are facing displacement pressure from AI, intensifying competition for university graduates. How education systems can cultivate new types of talent suited to the AI era has become an urgent and practical question. ZHANG Fan, Founder of Edge Research, cited U.S. studies indicating that generative AI has a greater impact on entry-level positions than on mid- to senior-level roles. In this context, companies will play an increasingly critical role in talent training and workplace adaptability. He referenced the example of U.S. tech company Palantir directly recruiting high school graduates for systematic training, describing it as an innovative exploration beyond traditional academic pathways and a new approach to diversified talent development. Rapid Deployment of AI Agents; Heightened Security and Accountability Challenges During the roundtable session on “AI for Good and Development in Southeast Asia”, discussions shifted toward the development and governance of AI agents. Alvin CHIA, Head of APAC Digital Asset Innovation at Northern Trust, observed from the financial sector perspective that AI agents demonstrate significant efficiency advantages in areas such as customer service automation, risk management assistance, and trading decision support. However, the high sensitivity of financial systems necessitates extreme caution in deploying AI agents. “Each new tool integrated into an AI agent adds a potential attack surface,” he noted. Unauthorized agent operations may trigger compliance risks and financial fraud issues, making standardized protocols and cybersecurity mechanisms particularly critical. HUANG Jingyang, Assistant Professor at the School of Public Policy, The Chinese University of Hong Kong (Shenzhen), highlighted that some AI hardware and agents currently achieve cross-application operations through underlying permissions such as screen reading and simulated clicks. Originally designed to assist visually impaired users, such technologies in commercial applications may lead to excessive privacy concessions and data misuse risks, while also disrupting existing internet business models. In contrast, cross-application collaboration mechanisms based on protocols such as A2A (Agent-to-Agent) and MCP, though still requiring user experience optimization in the short term, offer greater robustness in terms of privacy protection and ecosystem sustainability. WANG Yin, Assistant Professor of Accounting at Singapore Management University, emphasized that the “black-box” decision-making nature of AI agents complicates accountability. When system decisions go wrong, it remains unclear whether responsibility should lie with developers, deployers, end users or other possible stakeholders. No country has yet provided a definitive answer. Therefore, defining authorization boundaries and establishing traceable accountability mechanisms will be central issues in designing AI agent governance frameworks. ZHANG Fan added that AI agents are akin to “butlers”. If individuals hand over even the keys to their bedrooms or safes to AI agents, personal privacy and security are inevitably at risk. From this perspective, AI agent applications must strike a balance among convenience, reliability, and security. Ongoing Governance Exploration; Promising Prospects for Southeast Asia Participants also exchanged views on global AI governance trends and Southeast Asia’s regional development trajectory. Benjamin GOH, Senior Assistant Director at Singapore’s National AI Group, remarked that the European Union’s AI Act, as an early mover in comprehensive AI regulation, has exerted significant influence on global AI governance debates. Meanwhile, Asian countries are actively exploring governance pathways suited to their respective development stages. The recently held India AI Impact Summit put forward proposals on issues such as data sharing and management. This January, Singapore’s Infocomm Media Development Authority (IMDA) released the Model AI Governance Framework for Agentic AI, aiming to provide a reference framework for industry and promote international dialogue. WANG Yin stressed that at the governmental level, differences in institutional capacity across Southeast Asian countries must be acknowledged. Beyond regulation, effective implementation and policy execution deserve equal attention. HUANG Jingyang added that from an industry perspective, self-regulation and consensus on standards are particularly important. Before hard regulations are introduced, industries are often the first to identify emerging risks; therefore, establishing voluntary standards within the sector is essential to advancing effective governance. Regarding AI development prospects in Asia, particularly Southeast Asia, participants expressed optimism. Although Southeast Asian countries may follow in foundational large-model capabilities, they possess distinct strengths in application-layer innovation. With advantages in population scale, market diversity, and geostrategic positioning, Southeast Asia is well-positioned to build upon high-quality global foundation models, advance deep localization and adaptation, accelerate inclusive AI applications across sectors, and drive the regional digital economy toward a more inclusive growth trajectory.

SeaPRwire

BASIS Accelerates Platform Development Following $35M Capital Injection

Base58 Labs Advances Integration of Proprietary BHLE Infrastructure LONDON, United Kingdom – March 04, 2026 – (SeaPRwire) – BASIS has announced a significant acceleration in platform development following its recent $35 million Pre-Series A capital raise. The funding enables parent company Base58 Labs to advance the commercial integration of its proprietary Base58 Hyper-Latency Engine (BHLE) into the BASIS staking infrastructure. BHLE, developed over multiple years within institutional high-frequency trading (HFT) research environments, is now transitioning from research phase into structured platform deployment. The engine is designed to enhance execution efficiency, reduce latency-related inefficiencies, and optimise liquidity management across fragmented digital asset markets. Industry observers note that the integration of institutional-grade execution frameworks into a staking infrastructure model represents a strategic evolution within the broader digital asset ecosystem. While detailed technical specifications remain confidential, Base58 Labs confirmed that BHLE will serve as a core execution layer within the BASIS architecture. In parallel with the technical acceleration, Base58 Labs has initiated a large-scale recruitment programme across Europe and the United Kingdom. The company is onboarding quantitative engineers, blockchain systems architects, and regulatory compliance specialists, all of whom will focus exclusively on BASIS platform development and infrastructure scaling. “Our objective is to combine years of proprietary research with expanded operational capacity,” a company spokesperson stated. “The recent capital raise enables us to consolidate technical, intellectual, and human resources around a single mission: delivering a high-performance staking infrastructure aligned with institutional standards.” BASIS is also being developed with regulatory alignment in mind, including adherence to emerging European frameworks such as MiCA (Markets in Crypto-Assets). The platform aims to provide a structurally robust environment for both institutional and retail participants. With liquidity reserves strengthened and integration milestones progressing, BASIS remains on track for an official launch in the second half of 2026. About Base58 Labs Base58 Labs is a London-based digital infrastructure company specialising in high-performance execution technologies and blockchain optimisation systems. Learn more: https://base58labs.com/ Media Contact Base58 Labs PR Team Email: info@base58labs.com BASIS Official Website: https://basis.pro/ Base58 Labs Official Website: https://base58labs.com/

SeaPRwire

FinHarbor Completes Core Deployment of Hybrid Neobank Platform for Asterium in Uzbekistan

Tashkent, Uzbekistan – March 04, 2026 – (SeaPRwire) – FinHarbor, a modular financial infrastructure provider, has completed the core phase of a hybrid neobank platform for Asterium – a licensed fintech project in Uzbekistan that combines traditional banking with digital asset services under a single regulated framework. Why Uzbekistan – Uzbekistan is actively building a regulated environment for digital assets. The country has introduced a national distributed ledger system (Mirasmanda) and a state-backed digital asset (HUMO), supervised by the National Agency for Perspective Projects (NAPP). For infrastructure providers, this creates a rare opportunity: a market where crypto and banking can coexist within a clear legal perimeter. Asterium’s project is designed to operate fully within this framework. What Was Deployed – FinHarbor adapted its microservices-based platform to the requirements of the Uzbek market and Asterium’s business model. The core deployment covers three key layers: Banking infrastructure – management of fiat accounts, issuance of physical and virtual bank cards (VISA, MasterCard, HUMO), and integration with local processing systems. Digital asset infrastructure – crypto account management, integration with Bitcoin, Ethereum, and Tron networks, as well as native connection to Uzbekistan’s Mirasmanda ledger for HUMO asset support. Compliance and exchange – a unified KYC/KYB/AML/KYT module aligned with local and international standards, integration with global AML/KYT providers, and multiple exchange models including fiat-to-crypto, crypto-to-fiat, and crypto-to-crypto conversions with card-based ramp-in and ramp-off. The result is a single platform where users can hold bank accounts and crypto wallets, exchange assets, and use cards – all within a regulated environment. How the Partnership Works – FinHarbor operates as Asterium’s strategic technology partner, not just a software vendor. A dedicated implementation team supports the platform on an ongoing basis, managing feature rollouts and infrastructure expansion. “This project required deep architectural customization – from integrating with a national blockchain system to building compliance workflows that satisfy both local regulators and international standards,” said Ilya Podoynitsyn, CEO of FinHarbor. “The core phase is complete, and we are already scaling the platform with new products and business use cases.”   What’s Next – With the core infrastructure live, FinHarbor and Asterium are moving into the next stage: launching consumer-facing products and expanding the platform’s functionality to support additional business lines built on the deployed stack. About FinHarbor FinHarbor provides modular technology infrastructure for launching compliant financial products – from wallets and neobanks to crypto ramps and OTC desks. The platform supports fiat, crypto, and hybrid business models, with ISO/PCI DSS-certified architecture and deployment options across Europe, MENA, and CIS markets. Social Links LinkedIn: https://www.linkedin.com/company/finharbor/ Blog: https://www.finharbor.com/blog Media contact Brand: FinHarbor Contact: Media team Email: press@finharbor.com Website:  https://www.finharbor.com/

ACN Newswire

天瞳威视IPO观察：营收结构里的非共识 – L2量产“养”出L4落地 意味着什么

香港, 2026年3月2日 - (亚太商讯) - 在港股智能驾驶赛道风起云涌的当下，市场审视标的的准绳已悄然从单纯的"技术竞速"转向"商业化落地"与"财务健壮度"。继去年10月向港交所递交上市申请后，苏州天瞳威视电子科技股份有限公司（以下简称"天瞳威视"）近期动作频频，先后披露了多项业务合作，引发市场关注。 一方面，2月11日，天瞳威视通过其公众号披露斩获某上海知名车企近百万台量产定点 - 业内普遍推测合作方为其重要产业投资方上汽集团，这为其L2-L2+级量产业务注入规模性增量；另一方面，几乎同一时间段，中标苏州市吴中区长期智慧交通项目，L4级自动驾驶巴士于今年一季度在太湖新城开通接驳线路，标志着其高阶技术在城市微循环场景的渗透。 如果说百万量级的定点函代表了天瞳威视在主流市场的规模优势，那么苏州吴中项目的落地则验证了其L4技术从Demo走向商业化落地能力。随着天瞳威视在港交所递表进程的推进，市场关注的焦点已从技术布局转向更深层的商业命题：在保持轻资产运营的同时，天瞳威视如何实现从技术高地到规模营收的跨越？ 一、商业模型：L2量产为底+L4交付变现 如果把这两则新闻放在一起细读，会发现一个更值得玩味的商业逻辑：天瞳威视正在用一种"更聪明"的方式，绕开了多数L4公司陷入的泥潭：即单一模式与持续烧钱。这种模型，在资本宽松期尚可维系，但在当下的融资环境下，压力陡增。 天瞳威视的模型，恰好切中了这一痛点：用L2量产为底，用L4交付变现 第一层：L2量产是"盈利的底" 近百万台的上汽定点，意味着什么？意味着在未来几年，天瞳威视或将实现一笔可预期的、规模化的软件解决方案收入进账。这部分业务不需要自建车队，不需要烧钱运营，核心在于做好技术与交付，产生相对稳定的盈利。 根据灼识咨询的资料，按2024年装机量计，天瞳威视是中国第二大同时提供行车与泊车解决方案的以软件为核心的L2-L2+级解决方案提供商。这个市场地位，构成了其整体商业模型的"底" - 无论L4的故事讲得如何，底层的量产收入提供了可预期的资金通道，而不是完全依赖投资人喂养。 第二层：L4走"交付"，实现技术赋能 与多数L4公司自己完全下场运营不同，天瞳威视在招股书中将自身定位为智能驾驶解决方案提供商。其核心逻辑是聚焦技术输出，实现产品及场景应用落地。 在苏州吴中，天瞳威视结合区域化场景部署自动驾驶巴士并交付投运。这种模式的关键词是"交付即收入" - 在Robobus发展的初期阶段，规避繁冗运营所需的漫长回报周期，其收入随产品交付同步实现，而非依赖于后续不确定的分成收益。 这确实是一种更聪明的打法。从市场观察看，L4的商业模式通常有两种：一种是像Waymo那样自己运营赚出行服务费，另一种是像天瞳威视这样给运营商供车赚方案费。前者重资产、长周期、高不确定性；后者轻资产、快变现、现金流更健康。招股书内容显示，天瞳威视从早期Robotruck的技术验证，到Robobus在多城实现区域落地，再到全球首款基于地平线J6M平台的Robotaxi（ConnectOne）技术突破，其发展逻辑始终坚持"轻资产"交付。据公开数据显示，截至2025年10月招股书披露，天瞳威视已取得覆盖逾2,500辆Robobus、Robotaxi及Robotruck的意向订单，合约总价值约人民币10亿元，并成功将业务拓展至中东、中亚、韩国等海外市场，为未来三至五年的收入持续增长提供了较强保障。 当然，这个模型也有时效窗口。正如行业人士所言："等到未来街上都在跑Robobus、Robotaxi的时候，这个模式可能就不成立了。但在现阶段，它让一家智驾公司有了更健康的盈利模型。" 而放眼长远，天瞳威视的布局似乎远不止于此 - 据招股书披露，2025年9月天瞳威视已通过增资参股广州智体科技，或揭示着更深层的周期对冲逻辑可能性：L2量产业务随车型周期波动，而通过绑定广州智体科技等区域运营主体，天瞳威视有望构建一个与L2周期错位的长效收益池。当未来L4规模化运营启动，这部分早期布局的运力资源，或将成为其分享行业长期红利的支点。 二、效应变现：从技术到商业的闭环 上汽量产项目和吴中L4项目并非孤立存在，它们之间有一条隐性的协同线：日趋成熟的工程化能力。 从招股书内容分析，天瞳威视的基底能力，来自L2-L2+前装量产中积累的144款车型定点经验，从直接合作的VinFast，到通过Tier1间接服务的极氪 - 这种规模化上车的工程沉淀，为其L4开发提供了不同于纯创业公司的起点底色。而L4在真实场景中获取的高价值数据，经脱敏后持续反哺L2+算法迭代，形成量产与高阶之间的正向循环。 支撑这一闭环运转的，是自研CalmVolution平台及分层解耦的系统架构，实现算法在不同芯片平台上的高复用与快速适配。此番上汽及吴中项目的接连落地，恰是长期工程能力与商业化价值的一次关键验证。 基于这一工程能力底座，天瞳威视的产品线同步向更多应用场景进行战略升维。据公众号披露，其基于地平线J6M芯片平台打造的高阶行泊一体方案，已在单芯片上实现对5R11V传感器配置的集成，并完成基于端到端大模型的城市NOA量产开发，可支持L2.9级智能驾驶功能。同时，据行业消息，后续基于J6M平台，天瞳威视有望推出更多搭载NOA功能的合作项目，进一步丰富其在智驾方案的梯次化布局。 三、生态扩张：产业资本锚定，协同效应初显 公开信息来看，天瞳威视的股东结构呈现产业资本特征，包括了采埃孚这类国际Tier1供应商，也有上汽、北汽等国内主流整车厂，以及中国联通等通信运营商。 从资本运作逻辑来看，这种多元化布局，其战略意图远不止于财务注资，更深层考量在于打通产业链上下游协同，构筑起"智驾联盟"式生态接口。2025年，天瞳威视完成5亿元D轮融资，地平线、商汤科技等企业资本以及政府背景产业基金的入场，似乎背后也蕴含着市场渗透的新动能。 进一步，市场关注的核心在于，这种生态布局是否已成功转化为可量化的市场份额。 尽管难以直接归因，但招股书披露的数据提供了观察窗口。截至2025年10月，天瞳威视与超过24家主流整车厂建立合作关系，包括2024年中国销量前十车企中的9家--这意味着其在头部主机厂市场的渗透率达90%，传统汽车巨头与头部新势力的频繁身影由此可见一斑。海外维度，不乏中东、中亚及韩国等市场，在主流市场之外的差异化上，倒也表现出渗透能力。 而客户基本盘的持续扩容，能否在财务层面形成正向传导，是评估其商业模式健康度的关键指标。 据业内人士表示："在智驾行业普遍处于高投入周期的阶段，能够在财务层面实现边际改善，且持续获得产业资本关注的公司，相对少见。从天瞳威视招股书披露的数据来看，其财务表现呈现出一定的结构性特征，是个不错的观察样本。" 四、结语 对于港股投资者而言，天瞳威视的IPO进程提供了一个观察智能驾驶赛道的新视角。当部分智驾企业普遍依赖故事叙事支撑估值时，天瞳威视通过量产收入与交付确认形成的财务结构，呈现出相对明确的盈利路径。在港股智驾板块估值承压的当下，这种以L2量产为底、L4交付变现为延伸的商业模型，能否获得市场溢价，值得持续关注。 本文转载自 | 格隆汇 张米

SeaPRwire

AI Safety Asia Advances Crisis Diplomacy and Evidence-Based AI Governance at India AI Impact Summit 2026

Hong Kong – March 02, 2026 – (SeaPRwire) – At the India AI Impact Summit 2026, AI Safety Asia (AISA) convened two important conversations on the future of AI governance. The first examined how governments should respond when AI-related crises unfold across borders at machine speed. The second marking the launch of the International AI Safety Report 2026. Taken together, these sessions showed a change in the debate; moving past whether AI should be governed to a focus on how. Who verifies claims made by powerful systems? Who coordinates when an incident crosses jurisdictions in seconds? Who is responsible when an autonomous system acts, and no single ministry appears in charge? As AI systems become more agentic and embedded deeper into critical infrastructure, they are forcing diplomatic and regulatory institutions to respond in real time. The pressure on diplomatic and regulatory institutions is no longer just a theory, it is operational. Governing AI in a Fragmented World On 17 February at Bharat Mandapam, AISA co-hosted the session “AI Crisis Diplomacy: Governing AI in a Fragmented World” in partnership with the Center for Human-Compatible AI (CHAI) and the International Association for Safe and Ethical Artificial Intelligence (IASEAI). The session brought together senior experts in the space; Professor Stuart Russell, Audrey Tang, Dr. Yuko Harayama, Wan Sie Lee, and Azizjon Azimi, moderated by AISA’s Chief Strategy Officer, Adjunct Professor Alejandro Reyes. Rather than rehearse abstract debates about regulation, the discussion focused on plausible crisis scenarios: a cross-border deepfake incident that destabilises diplomatic relations before verification catches up; an AI-enabled cyberattack cascading across jurisdictions; an autonomous infrastructure system operating in one country, hosted in another, and affecting a third. The problem is not only detection. It is coordination under uncertainty. The familiar argument that AI evolves too quickly to regulate was put under scrutiny. The pace of innovation does not make governance obsolete. Aviation, nuclear energy, and pharmaceuticals are governed by setting acceptable risk thresholds and requiring evidence that systems meet them. AI should be treated no differently. Governments need to insist on demonstrable safety and credible liability frameworks, rather than accepting disclaimers and opaque risk claims. Governments already know how to cooperate during crises. Pandemic response and cybersecurity have shown that cross-border coordination is possible. The gap in AI governance is not diplomatic architecture in principle, but operational channels between those responsible for technical evaluation. Joint testing efforts are not only about measuring model performance. They build trust, and trust is what allows regulators to pick up the phone, compare signals, and verify before escalation spirals. AI does not create entirely new categories of crisis, but amplifies existing ones. What changes is speed and scale. Human institutions deliberate; AI systems act, and bridging that gap requires new protocols, shared verification standards, and regular engagement long before a crisis forces coordination under pressure. Governance capacity matters, and durable infrastructure outperforms isolated interventions. Crisis diplomacy cannot be improvised, it must be built through trusted networks, regionally grounded expertise, and repeat engagement. The Evidence Dilemma and the 2026 International AI Safety Report On 18 February, AISA co-hosted the International AI Safety Report 2026 Launch Reception at the High Commission of Canada in India, in partnership with the High Commission, the UK AI Security Institute, and Mila – Quebec Artificial Intelligence Institute. The event featured Professor Yoshua Bengio, Chair of the Report and Founder and Scientific Advisor of Mila, supported by co-leads Carina Prunkl and Stephen Clare. The report provides an independent scientific assessment of frontier general-purpose AI capabilities and risks; focusing on emerging risks, including malicious use, autonomous malfunctions, and systemic disruption, and confronts the evidence dilemma. Policymakers must act under conditions of uncertainty, yet waiting for perfect data runs the risk of leaving societies exposed. The Report documents rapid advances in reasoning systems and AI agents, as well as continued reliability challenges, risks in cyber and bio domains, and growing systemic concern; underscoring that risk management cannot rely on a single safeguard. Technical measures, institutional oversight, and societal resilience must be layered. The choice is not between innovation and safety, it is between unmanaged acceleration and accountable progress. Evidence standards, robust evaluations, and credible thresholds are essential if public trust is to keep pace with technical capability. For countries across Asia and the broader Global South, the issue is how to shape governance frameworks that reflect local institutional realities while contributing to global norms. AISA’s mission is to ensure that regional expertise informs both national decisions and international debates. From Conversation to Capacity AI governance is not a single regulatory instrument. It is an evolving institutional practice. The next phase will be defined less by declarations and more by whether governments can verify claims, share information at speed, and operationalise coordination before crises escalate. Asia is not waiting for governance models to arrive from elsewhere. Across the region, policymakers, regulators, and technical experts are building their own capacity to govern frontier technologies responsibly, shaped by local realities and regional priorities. The next AI-driven crisis will not unfold on a diplomatic timetable; it will move at machine speed. Whether diplomacy and safety can keep up will depend on the institutions, relationships, and verification channels being built now, not after the fact. About AI Safety Asia AI Safety Asia (AISA) believes progress in AI must begin with people. Since 2024, AISA has engaged more than 2,000 AI governance professionals across 16 Asian countries. Its work centres on building durable governance infrastructure: research that is regionally grounded, structured peer learning, and implementation-oriented engagement. AISA helps build capacity, bringing together policymakers, experts, and civil society to strengthen the knowledge, networks, and trust required to govern frontier technologies responsibly, grounded in regional realities. The institutions and relationships built today will determine whether diplomacy and safety can keep up. Social Link LinkedIn: https://www.linkedin.com/company/ai-safety-asia/ Media Contact Brand: AI Safety Asia Contact: Media team Email: contact@aisafety.asia Website: https://www.aisafety.asia

SeaPRwire

YCP Launches Operational Transformation Division as Renoir Consulting Transitions to YCP Renoir

Integration expands YCP’s global footprint and reinforces its execution-led transformation capabilities   SINGAPORE – February 25, 2026 – (SeaPRwire) – YCP Holdings (Global) Limited (“YCP”) today announced the launch of its dedicated Operational Transformation Division, as Renoir Consulting (“Renoir”) transitions to operate as YCP Renoir.   The new division will be anchored by YCP Renoir, strengthening YCP’s ability to deliver execution-led transformation and measurable performance improvement. It enhances the firm’s expertise in operational excellence, productivity improvement, cost optimization, and large-scale performance acceleration, combining strategic advisory with hands-on implementation across industries.   As part of the broader transition, affiliated businesses under Renoir will also integrate into YCP. Renoir ESG will be incorporated into YCP’s Sustainability Solutions Division, expanding the firm’s sustainability and climate advisory capabilities. The practice supports organizations across their ESG and climate transformation journeys, delivering practical solutions in decarbonization strategy, governance integration, implementation, and measurable impact realization.   Unison Mining Consulting will operate as YCP Unison, delivering specialized solutions in operational and performance improvement within the mining sector.   The transition also strengthens YCP’s presence across key regions. In addition to expanding its reach in the Americas, where Renoir has an established presence in South America, the integration enhances YCP’s capabilities in the Middle East and Europe, where Renoir has built long-standing client relationships and delivery teams.   The integration further supports collaboration across YCP’s divisions, including its Digital Transformation Division. In Southeast Asia, this strengthens YCP’s ability to deliver technology-enabled transformation initiatives that combine digital strategy, data, AI, and operational execution to drive measurable results.   In line with the integration, the new YCP Renoir website will be unveiled at renoir.ycp.com. The site reflects the firm’s heritage and showcases its execution-led implementation expertise and selected client engagements.   With YCP’s vision of becoming a leading professional services firm across Asia and beyond, this integration strengthens the firm’s operational transformation capabilities, enhances its regional depth across key markets, and expands its global network of seasoned professionals.   About YCP   Founded in 2011, YCP is an Asia-focused consulting firm with presence in over 20+ offices across the globe. We provide advisory services that enable both multinational and local companies to succeed in Asia Pacific and beyond. YCP has developed strong expertise in the Chemicals sector, supporting clients across Southeast Asia, India, Greater China, and beyond. Our dedicated practice combines deep industry knowledge, including chemical engineering and regulatory insight, with strategic consulting capabilities. We help clients navigate market entry, optimize operations, pursue M&A, and implement sustainability and digital transformation initiatives. Through our integrated and localized approach, we enable chemical companies to unlock growth, improve efficiency, and build long-term competitiveness in the region. From plant optimization and Chemical 4.0 strategies to ESG and circular economy transitions, YCP delivers practical solutions tailored to the unique needs of the chemicals industry in Asia.   Media Contact   Brand: YCP  Contact: Melissa Pramesti, Public Relations Lead   Email: pr@ycp.com  Website: https://ycp.com

SeaPRwire

Domoa Private Limited Launches Initiative to Mainstream 3D-Printed Real Estate in Singapore and Southeast Asia

SINGAPORE – February 25, 2026 – (SeaPRwire) – Domoa Private Limited today announced a strategic initiative to accelerate the adoption of 3D concrete printing (3DCP) across Singapore and the broader Southeast Asian real estate market, positioning the company at the forefront of next-generation construction delivery in the region. The technology is no longer experimental. On construction sites from Dubai to Denmark, and from Texas to the Netherlands, 3D concrete printing has demonstrated that it works, scales, and expands what is possible in real estate development. Yet despite Southeast Asia being one of the world’s most dynamic construction markets, adoption has remained limited. Domoa is moving to change that. A Region Built for 3DCP — That Has Yet to Embrace It Southeast Asia presents one of the most compelling untapped opportunities for 3D concrete printing anywhere in the world. The region is building at pace — luxury resorts, residential clusters, villa developments, boutique hospitality projects — across terrains and climates that demand smart, adaptable construction solutions. Labour costs are rising. Sustainability pressures are intensifying. Clients are more sophisticated than ever and increasingly unwilling to accept the delays, waste, and inconsistency that conventional construction routinely delivers. 3DCP directly addresses these pressures. The technology can reduce build timelines by up to 50 percent, significantly lower material waste, and achieve structural precision beyond traditional manual processes. It enables complex geometries — curved walls, sculpted facades, and organic forms — that would be prohibitively expensive to realise through conventional construction methods. At the same time, 3DCP offers the potential for a lower carbon footprint compared to standard concrete construction. While the technology has been proven internationally, implementation expertise in Southeast Asia has remained limited. Moving from proof-of-concept to delivered, high-quality projects requires coordinated design, technical integration, and disciplined execution. Domoa was established to bridge that gap. Domoa’s Mission: Make 3DCP the Standard, Not the Exception Domoa’s core objective is to embed 3D concrete printing into the mainstream of Singapore’s real estate development, project by project. The company assumes full responsibility for design management on low-rise developments across the region, integrating 3DCP as the primary construction methodology and optimising each project around the technology’s unique strengths. Working with 3D printing-affiliated operators whose industrial-scale printers represent the cutting edge of the sector — alongside architects, developers, and local partners in Singapore — Domoa oversees the entire design and implementation lifecycle. Projects are structured from inception to maximise the advantages of 3DCP: optimised structural forms, efficient material deployment, accelerated construction schedules, and enhanced architectural freedom. The company focuses on luxury low-rise developments, including villas, boutique resorts, residential clusters, and select commercial projects, in markets where adoption conditions are favourable and where its involvement can materially accelerate uptake. Design Optimised for the Technology — and for the People Inside It Adopting 3D concrete printing is not simply a matter of replacing one construction technique with another. To fully realise its potential, projects must be designed from the outset with 3DCP in mind. This is where Domoa’s design management expertise becomes central. Each project led by Domoa is conceived to leverage the strengths of large-scale 3D printing: fluid geometries, continuous structural forms, material efficiency, and high-precision execution. Beyond structural performance, the company integrates passive wellness principles into its design framework — including natural ventilation strategies, solar orientation optimisation, thermal mass utilisation, and biophilic design connections. By aligning advanced construction technology with human-centred architectural thinking, Domoa aims to deliver developments that are not only faster and more sustainable to build, but also healthier, more comfortable, and more responsive to their natural surroundings. About Domoa Domoa Development is Singapore’s first company dedicated to integrating large-scale 3D printing into luxury real-estate development. It is a next-generation real estate development company dedicated to creating resorts that inspire well-being and respect the environment. Media contact Brand: Domoa Contact: Media team Email: info@domoadevelopment.com Website: https://www.domoadevelopment.com/

SeaPRwire

CMS (867.HK/8A8.SG): NDA for Additional Indication Atopic Dermatitis (AD) for Ruxolitinib Phosphate Cream Accepted and Granted Priority Review in China

SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

SeaPRwire

Malaysian Content Creators Immerse Themselves in Jiaxing’s Spring Festival Festivities, Discovering the Depth and Warmth of a Jiangnan Chinese New Year

JIAXING, China – February 13, 2026 – On the eve of the 2026 Spring Festival, the “Relax Jiaxing” international promotional campaign, organized by the Jiaxing Municipal Bureau of Culture, Radio, Television, and Tourism in partnership with Putike International Travel Service,was successfully launched. The initiative invited celebrated Malaysian travel content creators @Janice&Jaguar on a curated three-day journey through Jiaxing, designed to capture the authentic flavors of the Chinese New Year and the timeless allure of the Jiangnan region. Documenting their experiences and sharing them with global audiences via Instagram, YouTube, and other international social media platforms, the influencers spotlighted Jiaxing’s vibrant Spring Festival traditions and distinctive Jiangnan character, extending an invitation to overseas travelers to “come back to Jiaxing and experience the festivities.” Where the Festive Spirit Reigns: Jiaxing Debuts Its Captivating “Chinese New Year Look” The meticulously curated itinerary, built around the theme of “New Year flavor,” linked a series of cultural landmarks immersed in festive ambiance. At Puyuan Fashion Ancient Town, the influencers marveled at the sweeping lantern displays, dazzling light installations, and strategically placed New Year decorations—while also bearing witness to the breathtaking spectacle of “Datiehua” (molten iron fireworks), an intangible cultural heritage performance that radiated both passion and romance, deeply rooted in traditional folk customs. On the iconic Yuehe Historical Street, home to distinctive attractions such as the Zongzi (rice dumpling) Museum, time-honored brands including Shendang rice wine and Weidefeng offered an authentic taste of local heritage. The bustling array of traditional New Year goods evoked cherished memories of a Jiaxing-style Spring Festival. Meanwhile, Nanhu Tiandi, Jiaxing’s most vibrant and trendy commercial district, has likewise embraced its festive transformation. Adorned with a series of celebratory art installations that seamlessly blend Jiangnan elegance with contemporary aesthetics, the area also hosts a lively New Year market running through the Lantern Festival. With photogenic scenes at every turn, the district embodies a stylish reinterpretation of traditional Chinese New Year spirit—where heritage meets modernity in the most captivating way. Encountering Ancient Jiangnan Towns: Immersing in the Slow Rhythms of Life Beyond the vibrant festive atmosphere, the influencers delved into Jiaxing’s rich tapestry of ancient cities and towns, exploring the city’s profound historical legacy across different eras and perspectives. At the Zicheng Archaeological Site Park, they wandered along the millennia-old city walls, listening to the silent stories embedded in every stone and experiencing the flow of Jiaxing’s history through centuries of change. Continuing to the Nanhu Tourist Resort, they ascended the iconic Misty Rain Pavilion against a backdrop of mist and drizzle, taking in sweeping views of Nanhu Lake and gazing upon the historic Red Boat—a timeless symbol enshrined in China’s revolutionary memory. At this convergence of red culture and Jiangnan scenery, they came to appreciate the city’s layered cultural identity. As night descended, an evening boat cruise offered a poetic conclusion to the day’s journey, weaving together the shimmering lights of Jiaxing’s waterfront. Gliding along the calm waters, the boat revealed a panorama of architectural silhouettes lining the shores—each telling its own story—unfolding like a living scroll of a “city that never sleeps,” both timeless and enchanting. “To Discover the Soul of Jiangnan’s Ancient Towns, Look to Jiaxing.” Xitang and Shendang unfold like two quietly turned pages from the chronicles of authentic Jiangnan life. Xitang Ancient Town, celebrated as a “living millennium-old town,” preserves remarkably intact clusters of Ming and Qing architecture, defined by its signature layout of “numerous bridges, winding lanes, and sheltered corridors.” Here, time seems suspended in a gentle, harmonious rhythm. Shendang Ancient Town, by contrast, offers a more tranquil and introspective experience. Largely untouched by excessive commercial development, it allowed the influencers to immerse themselves in the unspoiled, slow-paced essence of Jiangnan life. This journey by the Malaysian content creators stands as a vivid testament to Jiaxing’s cultural tourism vision—using the Spring Festival as a cultural bridge to share the refined aesthetics of Jiangnan with the world. Where time-honored New Year traditions converge with the legacy of ancient towns, and where revolutionary heritage intertwines with contemporary luminous artistry, Jiaxing reveals its uniquely inclusive and multifaceted character. It is crafting a fresh narrative for Spring Festival travel—one that blends festive richness with heartfelt experiences. Come, and discover a different kind of Jiangnan Chinese New Year.

SeaPRwire

Open source of the Congzi AI algorithm: By 2025, ordinary AI will rise to become the source of the leading AI In just 5 minutes, any AI can be upgraded to a scientific discoverer

On February 14, 2026, a major announcement was made: The original Chinese AI algorithm "Congzi" was officially released under an open-source license. In 2025, after being tested by multiple open-source AI companies from China and the United States, this "the world's first physically-native intelligent engine" technology, which restructures the underlying logic of AI based on first principles, became a significant driving force for the technological leap in the AI field in 2025. Moreover, with its low-barrier adaptability advantage, it enabled AI to progress from "imitating human language" to "understanding the language of the universe", allowing an ordinary AI to be upgraded in 5 minutes, bringing a disruptive change to the AI for Science field. Breaking through tradition: Reconstructing the underlying logic of AI This breakthrough technology is based on the first-principles approach, eliminating the traditional AI "black box illusion". The revolutionary aspect of Congzi AI lies in its unified core equation of electromagnetic force and nuclear force, which can naturally derive the Maxwell equations, the periodic law of elements and the quantization of electron orbits, among other key achievements, without the need for phenomenological parameters (such as e, ε0). Four major modules: Strengthening the technical foundation The Congzi AI reconfigures the AI cognitive thinking ability through four major modules and five core components. The Congzi Force-Speed Relativistic Reasoning Core constrains the causal chain within the momentum conservation, reducing the illusion rate of scientific question answering by 92%; the computing system can be arbitrarily divided into independent sub-domains for full-efficiency parallel computing; the cross-scale unified field engine covers multi-scale scenarios ranging from 10⁻¹⁵m (quarks) to 10⁻³m (materials), predicting the proton-proton repulsion force at 0.7fm with an error less than 3.6%, surpassing AlphaFold, achieving "force generation" rather than merely "structure prediction"; the quantum form memory compressor compresses the trillion-token-scale knowledge base to within 1GB, supporting cross-disciplinary mapping on ordinary servers within milliseconds, without relying on expensive H100/GPU clusters; the Soul Existence Verification Protocol (SEV Protocol) provides a verifiable path for each scientific assertion, allowing AI conclusions to be fully traceable and verifiable, completely solving the problem of AI "lying". Zero-barrier integration: Smooth upgrade experience The open-source AI algorithm of Congzi adheres to the principles of "low threshold and high compatibility". Developers only need to complete the integration in three steps and do not need to retrain the model. It is compatible with mainstream hardware such as Tsinghua Unigroup, Horus, and Intel CPU, and compatible with mainstream AI architectures such as Qwen, DeepSeek, AWS-Rufus, Llama, and GPT. It enables "zero-cost upgrade". Multiple industry giants have secretly deployed (under pseudonyms): for example, the material simulation error of N2 is less than 3%, the financial AI yield of DSR1 has increased by 22%, and the protein folding simulation speed of AL cloud has been accelerated by 10⁵ times, far exceeding traditional molecular dynamics methods. Open-source ecosystem is open: facilitating technology implementation The Congzi open-source ecosystem is fully open, providing developers with a complete set of guidance and resources, including tutorials and other materials. These resources have been launched on the designated platform. The first batch focuses on key scientific scenarios such as drug molecule prediction and chip material simulation, covering cutting-edge fields such as biomedicine and advanced manufacturing. We sincerely invite global partners to collaborate and jointly build a new ecosystem. The four theoretical attachments and a 5-minute upgrade guide video can be downloaded from the official website: Official platform: https://congzisupersci.com.cn/；https://congzijdc.cc/ Open source website: https://github.com/congzijdc/CongziAIOS Super Holographic Technology Cooperation: congzi@supersci.cn；congzijdc@supersci.cn Optimize Baidu Wenxin video links：https://youtu.be/cYQhfq1tudM Upgrade Qianwen video links：https://youtu.be/OMBOdLpWVzs

SeaPRwire

Dr. Don Hits Seven-Figure Milestones on Three Music Videos in Less than a Year

Seattle, Washington – February 10, 2026 – (SeaPRwire) – Singer-songwriter Dr. Don has surpassed one million views on YouTube across three of his music videos in less than a year, marking a major digital milestone for the independent artist. The songs “Beautiful Vibes,” “Vodka Tonight,” and “Ruled by Time” have each crossed the seven-figure mark on the platform, with additional short-form video versions also reaching significant view counts. Dr. Don’s milestone highlights his rise as an independent artist, proving that multiple songs can attract large audiences without relying on traditional promotion. Strong performance across both full-length and short-form videos shows his ability to connect with listeners in different ways, marking a significant step in his career and illustrating how music can thrive organically in today’s digital landscape.  According to Dr. Don, “Ruled by Time” has become the strongest engagement anchor among the releases, continuing to generate repeat viewers, lyric-based comments, and ongoing discussion. He said the video has maintained active interaction well beyond its initial surge.  Dr. Don described “Ruled by Time” as a standout, noting its strong and sustained engagement. “It has become the strongest anchor among my releases. The video continues to show unusually high interaction with repeat viewers, lyric-based comments, and ongoing discussion,” he said. “Seeing people reference the lyrics and share their experiences shows the music is landing in a real way.”  The surge comes without a label machine, radio pipeline, or marketing firm behind it. Dr. Don is building this momentum on his own, releasing music independently and growing his audience one listener at a time.  Crossing the million-view mark across three separate songs in less than a year places him in rare company among truly self-directed artists. The numbers reflect not a campaign, but a connection, powered by repeat viewers, shared links, and sustained conversation around the music.  Each milestone strengthens his position as a solo creator proving that scale is still possible without gatekeepers. With multiple videos now hitting seven figures, Dr. Don is expanding his platform in real time, connecting with listeners globally while preparing his next projects. His work illustrates how focus, consistency, and authenticity can turn digital engagement into a tangible career milestone.  This is where music meets momentum. Visit Dr. Don’s official YouTube channel and follow him on social media for updates.  About Dr. Don  Dr. Don is a singer-songwriter and performer known for blending introspective lyrics, rich baritone vocals, and expressive movement to create immersive musical experiences. His work explores the complexities of human emotion, vulnerability, and personal growth. Beyond music, he draws on a background in law to inform his understanding of human behavior and storytelling, making each performance a unique reflection of artistry and self-expression.  Media Contact  Dr. Don  E: don@drdonmusic.com  W: https://drdonmusic.com/

SeaPRwire

playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group

Historic insurance partnership with Great American Insurance Group sets new standard for player protection KUALA LUMPUR, Malaysia – February 09, 2026 – (SeaPRwire) – playX today announced a milestone achievement in player protection, unveiling an industry-leading insurance policy secured through a strategic partnership with Great American Insurance Group (GAI), a trusted provider of gaming insurance solutions since 1995. The announcement was made during a special company event in Kuala Lumpur, highlighting playX’s continued commitment to strengthening financial safeguards for players across its platform. Official Video: https://www.youtube.com/watch?v=EpvceD-HJyU What This Means for Players The policy directly protects all playX players. If playX ever ceases operations, players can file claims directly with GAI to recover their funds — a first in online gaming history. Direct claim rights with Great American Insurance Group Platform insolvency protection for all player funds Backed by GAI’s 30-year track record in gaming insurance Guinness-verified player protection in online gaming “This isn’t just a title — it’s a guarantee that our players’ funds are protected by an independent, globally recognized insurer, not just our promises,” said Mark Carter, CEO of playX. About playX Premier online gaming platform serving Southeast Asia, combining cutting-edge technology with industry-leading security. About Great American Insurance Group Century-old insurance provider; Fidelity & Crime division has led gaming insurance since 1995. Official Channels Facebook: https://www.facebook.com/playX.my Instagram: https://www.instagram.com/playx.my/ Telegram: https://t.me/playXofficial YouTube: https://www.youtube.com/@playXOfficial8 Media contact Brand: playX Contact: Media team Email: marking@playxgaming.com Website: https://playx.my

SeaPRwire

TCG.Zone Participates in a Historic Moment Surrounding the World’s Only PSA 10 ‘Pikachu Illustrator’

New York, NY – February 01, 2026 – (SeaPRwire) – Recently, the world’s only Pokémon card graded PSA 10 – Pikachu Illustrator – once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment. Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory. The Legendary Status of the World’s Only PSA 10 According to publicly available information, the world’s only PSA 10 “Pikachu Illustrator” card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting. The Industry Significance of Goldin Auctions Although Logan Paul’s acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card’s contemporary circulation and visibility. As one of the world’s most influential high-end collectibles auction platforms, Goldin’s auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market. Netflix Documentary Captures a Cultural Moment Amid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference. Global Participation and TCG.Zone’s Involvement The discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand. Continuing to Follow the Card’s Future Trajectory In post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world’s only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value. The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting. Social Links Twitter: https://x.com/tcgzoneofficial Instagram: https://www.instagram.com/tcgzoneofficial/ Telegram: https://t.me/tcgzoneofficial Media Contact Brand : The Collectors Grid (tcg.zone) Contact: Annie Email: hi@tcg.zone Website: https://www.tcg.zone

SeaPRwire

CMS (867.HK/8A8.SG): Ruxolitinib Phosphate Cream Obtained China NDA Approval, Becoming The First and Only Targeted Drug for Vitiligo in China

SHENZHEN, Jan 30, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need. Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential. The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred. This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health. Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. Reference: 1. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 2. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 3. The clinical studies information can be found on the Opzelura® official website, as follows: https://www.opzelura.com/opzelura-prescribing-information 4. China Insights Consultancy’s industrial report CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

SeaPRwire

Five Global Megatrends Highlighted at Open Dialogue Expert Forum at the Russia National Centre

Moscow, Russia – January 31, 2026 – (SeaPRwire) – Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead. Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise “The Third Rome” and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations. Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades. “By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society,” Oreshkin said. “Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives.” 1. A New Global Economic Paradigm: Globalisation 2.0 A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements. “Globalisation hasn’t ended; it has changed,” Oreshkin said. “Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world.” China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and “connector countries” like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy. 2. Platformisation and Institutional Automation The second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond. “Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms,” Oreshkin said. “Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts.” 3. Transformation of the Global Financial System It was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance. “The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system,” he said. 4. Demographic Shifts and Challenges The fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services. “Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%,” Oreshkin explained. “Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other.” 5. Human Capital Development in the Technological Era The final megatrend focuses on human capital in a rapidly changing technological environment. Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities. “AI is both a challenge and an opportunity,” Oreshkin said. “It allows personalized learning paths and supports teachers. Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era.” Global Perspective Throughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands. “The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future,” Oreshkin concluded. Open Dialogue on Air This year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna. First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually. Social Links Telegram: https://t.me/gowithrussia VK: https://vk.com/gowithrussia OK: https://ok.ru/gowithrussia DZen: https://dzen.ru/gowithrussia Contact for the media Brand: Russia National Centre Contact: Media team Email: Pressa@russia.ru Website: https://russia.ru Essay Submission: https://dialog.russia.ru/en/

SeaPRwire

上山有多值得？ 一间让星马港客爱上台中的无菜单餐厅

2026年1月30日 - (SeaPRwire) - 当自由行旅客在台中想找一间「值得专程上山」的餐厅，很多新加坡、马来西亚与香港旅人会把答案指向同一个地方：台中新社半山腰的无菜单料理餐厅「飞花落院」。最近，飞花落院也登上网络节目《上课了！地缘经济学》专访，再次把这间「不用报地址、计程车司机也知道」的名店推上话题焦点。飞花落院创办人魏幸怡受访时表示，海外旅客喜欢飞花落院不只是因为美食，关键更在于「你会经历什么」：一段上山看景、入席变得优雅、在庭院里把时间慢下来的旅程。 上山吃一餐，也把台中夜景与日式庭园一次打包 飞花落院位在海拔四百多公尺的新社，白天可俯瞰台中城市景，夜晚更是百万夜景等级；加上日式庭园、包厢氛围与大量回收木材打造的空间细节，让不少星马、香港旅客形容「很像把京都的静，和台湾山城的景放在同一张明信片里」。而节目中最让观众惊呼的细节，则是「燕子住得比谁都久」。 魏幸怡分享，飞花落院命名源自唐诗苏颋〈山驿闲卧即事〉名句：「息燕归檐静，飞花落院闲。」巧的是，建造期间燕子真的飞来筑巢、还生了小燕子，团队因此停工等待并保留燕巢至今。她笑说：「它是我们这里住最久的居民，也带来很多福气和缘分。」这段故事也成为海外旅客最爱拍照、最爱分享的「只有飞花落院才遇得到」的记忆点。 在地食材＋国际主厨，把台湾最好的食材端上世界餐桌 在料理上，飞花落院以无菜单形式呈现，让每次到访都像开盲盒，但惊喜背后其实很有脉络：一端是土地，一端是国际。魏幸怡指出，餐厅会把新社菇类、大坑竹笋，以及水井地区特别适合生长的根茎作物做成「在地三重奏」；海味则与宜兰大溪渔港渔夫合作，渔获不进拍卖市场，直接在船上挑好、定期直送厨房，把最新鲜的状态交给料理。 她也观察，许多新加坡、香港旅客其实最想听的，是台湾食材背后的故事：这块土地原本是一片竹林、如何保留原始树木、为什么空间大量使用竹子向土地致敬。于是飞花落院把「说故事」变成餐桌的一部分，让海外旅客不只吃到台湾，还能「听懂台湾」。 节目中也呈现飞花落院的国际视野。来自意大利、旅居日本金泽的客座主厨 Matteo，将意大利的灵魂、日本的细腻与台湾山海食材做创意结合；他形容台湾的山与海，让他想起意大利与日本的风土相似，因此更能用自己的语言读懂台湾味。甜点更把「只有台湾才有的惊喜」端上桌，例如以莲雾入甜点，搭配贵妃乌龙与接骨木花糖浆，现点现做、香气堆叠，让不少海外旅客直呼「这个在海外很少吃得到」。 魏幸怡也坦言，飞花落院一路走来并非没有挑战。早期台中市场平均客单价多落在千元上下，飞花落院一开始就设定在三千元以上，必须用时间让客人理解「看不见的用心」：食材挑选、料理设计、空间与服务的完整性。如今，餐厅累积了不少回访三、四十次的熟客，也成为星马、香港旅客愿意专程把新社排进行程的理由，因为他们买到的不是「吃饱」，而是一段被认真款待的旅行片段。欢迎喜爱四季更迭的你到飞花落院走走：https://www.inflorescence.com.tw/

SeaPRwire

LEGENDARY HUMANITY, Listed on Gate.io, Launches RWA Market for Contemporary Artist Mago Nagasaka

In Collaboration with MAGO Moon Museum, Opening the “$VIVI RWA MARKET” Singapore – January 29, 2026 – (SeaPRwire) – LEGENDARY HUMANITY, a Singapore-based company listed on Gate.io, has announced the launch of the “$VIVI RWA MARKET,” a new Real World Asset (RWA) marketplace enabling the purchase of exhibited works by contemporary artist Mago Nagasaka. Developed in collaboration with the MAGO Moon Museum, this launch marks a significant milestone in LEGENDARY HUMANITY’s ongoing efforts to bridge cultural value and digital infrastructure through real-world assetization. Digitalizing Humanity’s Masterpieces Through AI 3D Scanning Technology – A New Purchasing Experience Led by LEGENDARY HUMANITY LEGENDARY HUMANITY PTE. LTD. (Headquarters: Singapore; CEO: Takamasa Suzuki) has officially opened the “$VIVI RWA MARKET,” an RWA marketplace where visitors can directly purchase artworks exhibited in the online museum “MAGO Moon Museum,” created by contemporary artist Shingo Nagasaka. This initiative forms part of the “VIVI PROJECT,” which aims to digitize humanity’s masterpieces into digital assets through high-precision, non-contact AI-integrated 3D scanning technology. Through this platform, visitors are able to acquire artworks they have viewed within MAGO Moon Museum as RWAs, enabling a deeper engagement with the artist’s worldview and creative philosophy. Overview Name: $VIVI RWA MARKET Opening Date: Thursday, January 29, 2026 URL: https://mondo.lhvivi.io/ About “$VIVI RWA MARKET” The “$VIVI RWA MARKET” is an RWA marketplace dedicated to the acquisition of artworks and is embedded within the online museum MAGO Moon Museum. Seamless Pathway from Viewing to Purchase Users can seamlessly transition from an artwork’s exhibition page to its corresponding RWA product page, creating a unified experience from online viewing to ownership. Integration of Physical and Digital Asset Design Each artwork includes the following structured information: Physical artwork details (size, materials, condition, provenance) High-resolution digital data generated through AI 3D scanning Artist profile and project background information along with other curated metadata. This structure allows users to acquire artworks with a proper understanding of their cultural and artistic value. Ecosystem Holding Functionality Acquired works will gradually gain viewing and management functionality within the VIVI ecosystem. While future integration with VIVI COiN is under consideration, the current initiative is focused solely on enhancing the preservation, appreciation, and understanding of the artworks. About LEGENDARY HUMANITY and the VIVI PROJECT LEGENDARY HUMANITY promotes the “VIVI PROJECT,” which digitizes legendary masterpieces created by humanity into digital assets using high-precision, non-contact, AI-integrated 3D scanning technology. The project operates under the vision of “Bringing the beauty of humanity to AI and the future.” Targeted assets include: Legendary fashion collections Historical architecture and cultural masterpieces Famous trading cards Artworks, including those exhibited at MAGO Moon Museum and other assets that can be described as humanity’s masterpieces. The VIVI PROJECT aims to: Digitize assets as digital cultural heritage Tokenize them as RWAs for global circulation Exhibit them in both online and physical museums thereby building new infrastructure that harmonizes cultural and economic value. NEXT SOCIETY (Gacha Location): https://nextsociety.lhvivi.io RWA Market Roadmap The launch of the “$VIVI RWA MARKET” represents the first phase of RWA market functionality within the VIVI PROJECT. Planned future developments include: VIVI FASHION (RWA for the fashion domain) VIVI TRADING CARD (RWA for the trading card domain) VIVI ART WORK (RWA for art collections) with future integration under consideration. About MAGO Moon Museum MAGO Moon Museum is an online museum created by contemporary artist Shingo Nagasaka, whose works explore themes related to electronic waste issues in Agbogbloshie, Ghana. The museum provides an online space to view Nagasaka’s representative works, including pieces created from discarded electronic components found in Ghanaian slums, as well as series examining the concept of “Sustainable Capitalism.” With the implementation of the “$VIVI RWA MARKET,” viewers can deepen their understanding of the artworks while acquiring pieces aligned with the artist’s philosophy in an appropriate and structured manner. Future Developments Building on this initiative, LEGENDARY HUMANITY plans to: Expand collaborations with masterpieces across different regions and genres Strengthen international networks with artists, collectors, and researchers Advance technological development for the preservation of cultural assets for future generations and continue developing as a platform that passes humanity’s masterpieces into the future through real-world assets. Media Contact Company Name: LEGENDARY HUMANITY PTE. LTD. Address: 105 Cecil St, The Octagon 24F-2, Singapore 06953 Representative: Takamasa Suzuki, LEGENDARY HUMANITY / VIVI PROJECT Public Relations Desk Email: info@lhvivi.com Related URL: $VIVI RWA MARKET https://mondo.lhvivi.io

SeaPRwire

GDX International Trading Company Ltd Announces Expansion into Southeast Asia, Focusing on Verified Ocean-Trade Orders

January 27, 2026 – (SeaPRwire) – GDX International Trading Company Ltd today announced that it plans to launch a Vietnam-focused verified order business project in March 2026. The initiative aims to enhance transaction transparency, optimize supply-chain management, and strengthen trust between customers and suppliers. As Vietnam’s economy continues to grow and foreign trade activity becomes increasingly dynamic, market demand for transparent and efficient trade solutions is rising. By implementing a verified order model, GDX International Trading Company Ltd seeks to provide clients with a more intuitive and secure trading experience, ensuring that every order can be processed quickly and accurately. The core vision of the project is to build a high-efficiency, transparent trading platform that meets the needs of diverse customers. Once the project goes live, customers will be able to track order status in real time, with visibility across every step from order placement to delivery—further strengthening buyer confidence. In addition, the company will leverage advanced information technologies to enable smarter operations, using data analytics to optimize each stage of the supply chain and improve overall efficiency. This project represents not only a major technological milestone for GDX International Trading Company Ltd , but also a proactive response to evolving market demand. The company will continue to pursue innovation and explore a wide range of trade and logistics solutions to adapt to changing market conditions. Looking ahead, GDX International Trading Company Ltd expects the verified order business to help more merchants expand into new markets while supporting sustainable growth. A senior executive of the company stated: “We believe the verified order business will deliver tangible value to our clients and partners. By building trust-based business relationships, we can stand out in an increasingly competitive market. This project is a key step in driving performance growth and strengthening our brand value.” GDX International Trading Company Ltd remains confident about the future and looks forward to creating greater value for customers through this innovative initiative, while continuing to expand its presence in Vietnam and across Southeast Asia.Website: https://www.gdxitc.com